Live News

Correction: Tegileridine: First Approval

Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...

Drugs

0 0

Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses

Although paracetamol (acetaminophen) combined with other analgesics can reduce pain intensity in some pain conditions, its...

Drugs

0 0

Tunlametinib: First Approval

Tunlametinib (科露平®) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK ...

Drugs

0 0

Zolbetuximab: First Approval

Zolbetuximab (VYLOY™), a recombinant, chimeric, anti-claudin 18.2 (CLDN18.2) monoclonal antibody (mAb), is being dev...

Drugs

0 0

Mavorixafor: First Approval

Mavorixafor (XOLREMDI™) is an oral, selective C-X-C chemokine receptor 4 (CXCR4) antagonist developed by X4 Pharmace...

Drugs

0 0

Bone Fragility in Diabetes and its Management: A Narrative Review

Bone fragility is a serious yet under-recognised complication of diabetes mellitus (DM) that is associated with significan...

Drugs

0 0

Elafibranor: First Approval

Elafibranor (IQIRVO®) is a first-in-class peroxisome proliferator-activated receptor (PPAR) agonist being developed b...

Drugs

0 0

Anticoagulation in Chronic Kidney Disease

The nuanced landscape of anticoagulation therapy in patients with chronic kidney disease (CKD) presents a formidable chall...

Drugs

0 0

Imetelstat: First Approval

Imetelstat (RYTELO™), an oligonucleotide telomerase inhibitor, is being developed by Geron Corporation for the treat...

Drugs

0 0

Ensifentrine: First Approval

Ensifentrine, an inhaled, selective phosphodiesterase (PDE) 3 and PDE4 inhibitor, is being developed by Verona Pharma plc ...

Drugs

0 0

Cefepime–Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination

Taniborbactam (formerly known as VNRX-5133) is a novel bicyclic boronate β-lactamase inhibitor of serine β-lacta...

Drugs

0 0

Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis

Clopidogrel is widely used for the secondary prevention of atherothrombotic events in patients with coronary artery diseas...

Drugs

0 0

Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses from Two Phase III Trials

The purpose of this study was to conduct and interpret a pooled 12-month analysis of two prospective, multi-center, random...

Drugs

0 0

Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape

Successful antimicrobial therapy depends on achieving optimal drug concentrations within individual patients. Inter-patien...

Drugs

0 0

Donanemab: First Approval

Donanemab (donanemab-azbt; KisunlaTM) is an amyloid β-directed antibody developed by Eli Lilly and Company for the tr...

Drugs

0 0

Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials

Nonalcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver diseas...

Drugs

0 0

The Pharmacological Landscape for Fatty Change of the Pancreas

The quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medica...

Drugs

0 0

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree®...

Drugs

0 0

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

The COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly 7 million deaths, according to th...

Drugs

0 0

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sa...

Drugs

0 0

Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo

Topical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in ...

Drugs

0 0

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Dr...

Drugs

0 0

Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders

The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several deg...

Drugs

0 0

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease

Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and ...

Drugs

0 0

Bimekizumab: A Review in Psoriatic Arthritis

Although several biological disease-modifying antirheumatic drugs (bDMARDs), including interleukin (IL)-17A inhibitors, ar...

Drugs

0 0

Crovalimab: First Approval

Crovalimab (派圣凯®; PiaSky) is a humanized, anti-complement component C5 (anti-C5) recycling monoc...

Drugs

0 0

Cefepime/Enmetazobactam: First Approval

Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cep...

Drugs

0 0

Tegileridine: First Approval

Tegileridine (艾苏特) is a small molecule μ-opioid receptor biased agonist developed by Jiangsu Hen...

Drugs

0 0

Resmetirom: First Approval

Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal ...

Drugs

0 0

Drugs in Development to Treat IgA Nephropathy

IgA nephropathy is a common glomerulonephritis consequent to the autoimmune response to aberrant glycosylated immunoglobul...

Drugs

0 0

Categories

Channels

SCI Abstract